Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary Artery Lesions

Coronary Artery Disease Clinical Trial

— 3D  

Official title:

A Randomized Feasibility Study of the Double Dose or Single Dose Sirolimus-Eluting BX VELOCITY Balloon-Expandable Stent for the Treatment of Diabetic Patients With de Novo Native Coronary Artery Lesions(3D)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00233714
• Other study ID #: P03-6318
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: October 4, 2005
• Last updated: November 17, 2009
• Start date: May 2003
• Est. completion date: November 2009

Study information

• Verified date: November 2009
• Source: Cordis Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of HealthItaly: Ministry of HealthBrazil: National Committee of Ethics in Research
• Study type: Interventional

Clinical Trial Summary

The main objective of this study is to assess safety and effectiveness of double dose sirolimus-eluting Bx VELOCITY stents in diabetic patients with a de novo native coronary lesion, as compared to single dose sirolimus-eluting Bx VELOCITY™ stents.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: November 2009
• Est. primary completion date: July 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient must be minimum 18 years of age;

2. Patients must be previously diagnosed with diabetes with documented treatment with insulin, oral medications, or diet for a minimum of 3 months;

3. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;

4. Treatment of one lesion in a native coronary artery. The treated lesion will be the one with the highest % diameter stenosis by visual estimate. Additional study stents may be used for procedural complications such as dissections. Multivessel treatment is permissible in non-target vessels; however, additional lesions may only be treated with commercial stents. If other non-target lesions are treated with commercial stents during the index procedure, they must be successfully treated prior to the study lesion;

5. The target vessel is 2.5 mm and 3.5mm in diameter (visual estimate);

6. The target lesion is <30 mm in length (visual estimate) located in a native coronary artery;

7. Target lesion stenosis is >50% and <100% (TIMI I) (visual estimate);

Exclusion Criteria:

1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment;

2. Patients admitted for treatment of diabetic ketoacidosis > 2 times in the past six months (Brittle Diabetics);

3. Ejection fraction 30%;

4. Impaired renal function (creatinine > 2.0 mg/dL);

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• CYPHER Sirolimus-Eluting Coronary Stent
Single dose Sirolimus-Eluting coronary stent
• CYPHER Sirolimus-Eluting Coronary Stent
Double-dose Sirolimus-Eluting coronary stent

Locations

Country	Name	City	State
Brazil	Institute Dante Pazzanese of Cardiology	Sao Paolo

Sponsors (1)

Lead Sponsor	Collaborator
Cordis Corporation

Country where clinical trial is conducted

Brazil, 

References & Publications (2)

Costa RA, Sousa JE, Abizaid A, Chaves A, Feres F, Sousa AG, Musumeci G, Mehran R, Fitzgerald PJ, Lansky AJ, Leon MB, Shiran A, Halon DA, Lewis BS, Guagliumi G. The randomised study of the double dose versus single dose sirolimus-eluting stent for the trea — View Citation

Hur SH, Ako J, Shimada Y, Tsujino I, Hassan AH, Abizaid A, Shiran A, Lewis BS, Guagliumi G, Cohen SA, Honda Y, Fitzgerald PJ, Sousa JE. Two-year intravascular ultrasound observations in diabetic patients treated with single and double dose sirolimus-eluti — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is in-stent late lumen loss as measured by QCA at 6 months post-procedure.		6 months post-procedure	Yes
Secondary	Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure.		30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure	Yes
Secondary	Target lesion revascularization (TLR) and target vessel revascularization (TVR) at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure.		30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure	Yes
Secondary	Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization at 30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure.		30 days, 6 months, 12 months and 2, 3, 4 and 5 years post-procedure	Yes
Secondary	Device success defined as achievement of a final residual diameter stenosis of <50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.		During Index Procedure	Yes
Secondary	Lesion success defined as the attainment of <50% residual stenosis (by QCA) using any percutaneous method.		During Index Procedure	No
Secondary	Procedure success defined as achievement of a final diameter stenosis of <50% (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay.		During the hospital stay	Yes
Secondary	In-stent and in-lesion binary restenosis (> 50% diameter stenosis) as measured by QCA at 6 months and 2 years.		6 months and 2 years	Yes
Secondary	In-stent and in-lesion mean percent diameter stenosis (%DS) and minimal lumen. diameter (MLD) measured by QCA post-procedure and at 6 months and 2 years.		post-procedure and at 6 months and 2 years	Yes
Secondary	In-lesion late lumen loss measured by QCA at 6 months and 2 years.		6 months and 2 years	Yes
Secondary	Stent lumen and stent obstruction volume by intravascular ultrasound (IVUS) at post-procedure and 6 months and 2 years.		post-procedure 6 months and 2 years.	Yes
Secondary	Glycemic control as measured by HbA1c at baseline, 6, 12, and 24 months.		baseline, 6, 12, and 24 months	Yes
Secondary	C-reactive protein levels measured at baseline, 6, 12, and 24 months related to patient outcomes.		baseline, 6, 12, and 24 months	Yes